Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 106

1.

Reversible inhibition of calcium oxalate monohydrate growth by an osteopontin phosphopeptide.

Nene SS, Hunter GK, Goldberg HA, Hutter JL.

Langmuir. 2013 May 28;29(21):6287-95. doi: 10.1021/la400891b. Epub 2013 May 16.

PMID:
23611580
2.

Control of calcium oxalate crystal growth by face-specific adsorption of an osteopontin phosphopeptide.

Grohe B, O'Young J, Ionescu DA, Lajoie G, Rogers KA, Karttunen M, Goldberg HA, Hunter GK.

J Am Chem Soc. 2007 Dec 5;129(48):14946-51. Epub 2007 Nov 10.

PMID:
17994739
3.

Kinetics of calcium oxalate crystal growth in the presence of osteopontin isoforms: an analysis by scanning confocal interference microcopy.

Langdon A, Wignall GR, Rogers K, Sørensen ES, Denstedt J, Grohe B, Goldberg HA, Hunter GK.

Calcif Tissue Int. 2009 Mar;84(3):240-8. doi: 10.1007/s00223-008-9215-5. Epub 2009 Feb 3.

PMID:
19189038
4.

Molecular modulation of calcium oxalate crystallization.

De Yoreo JJ, Qiu SR, Hoyer JR.

Am J Physiol Renal Physiol. 2006 Dec;291(6):F1123-31. Review.

5.

Label-free mapping of osteopontin adsorption to calcium oxalate monohydrate crystals by tip-enhanced Raman spectroscopy.

Kazemi-Zanjani N, Chen H, Goldberg HA, Hunter GK, Grohe B, Lagugné-Labarthet F.

J Am Chem Soc. 2012 Oct 17;134(41):17076-82. doi: 10.1021/ja3057562. Epub 2012 Oct 3.

PMID:
22991940
6.

On the catalysis of calcium oxalate dihydrate formation by osteopontin peptides.

Chan BP, Vincent K, Lajoie GA, Goldberg HA, Grohe B, Hunter GK.

Colloids Surf B Biointerfaces. 2012 Aug 1;96:22-8. doi: 10.1016/j.colsurfb.2012.03.015. Epub 2012 Mar 29.

PMID:
22503630
7.

Role of phosphate groups in inhibition of calcium oxalate crystal growth by osteopontin.

Hunter GK, Grohe B, Jeffrey S, O'Young J, Sørensen ES, Goldberg HA.

Cells Tissues Organs. 2009;189(1-4):44-50. doi: 10.1159/000151430. Epub 2008 Aug 15.

PMID:
18703867
8.

Phosphorylation of osteopontin peptides mediates adsorption to and incorporation into calcium oxalate crystals.

O'Young J, Chirico S, Al Tarhuni N, Grohe B, Karttunen M, Goldberg HA, Hunter GK.

Cells Tissues Organs. 2009;189(1-4):51-5. doi: 10.1159/000151724. Epub 2008 Aug 26.

PMID:
18728346
9.

The osteopontin-controlled switching of calcium oxalate monohydrate morphologies in artificial urine provides insights into the formation of papillary kidney stones.

Langdon A, Grohe B.

Colloids Surf B Biointerfaces. 2016 Oct 1;146:296-306. doi: 10.1016/j.colsurfb.2016.06.030. Epub 2016 Jun 16.

PMID:
27362921
10.

Modulation of calcium oxalate dihydrate growth by selective crystal-face binding of phosphorylated osteopontin and polyaspartate peptide showing occlusion by sectoral (compositional) zoning.

Chien YC, Masica DL, Gray JJ, Nguyen S, Vali H, McKee MD.

J Biol Chem. 2009 Aug 28;284(35):23491-501. doi: 10.1074/jbc.M109.021899. Epub 2009 Jul 6.

11.

Modulation of calcium oxalate crystallization by linear aspartic acid-rich peptides.

Wang L, Qiu SR, Zachowicz W, Guan X, Deyoreo JJ, Nancollas GH, Hoyer JR.

Langmuir. 2006 Aug 15;22(17):7279-85.

PMID:
16893227
12.

Specific adsorption of osteopontin and synthetic polypeptides to calcium oxalate monohydrate crystals.

Taller A, Grohe B, Rogers KA, Goldberg HA, Hunter GK.

Biophys J. 2007 Sep 1;93(5):1768-77. Epub 2007 May 11.

13.

Cooperation of phosphates and carboxylates controls calcium oxalate crystallization in ultrafiltered urine.

Grohe B, Chan BP, Sørensen ES, Lajoie G, Goldberg HA, Hunter GK.

Urol Res. 2011 Oct;39(5):327-38. doi: 10.1007/s00240-010-0360-8. Epub 2011 Jan 14.

PMID:
21234554
14.

Attachment of calcium oxalate monohydrate crystals on patterned surfaces of proteins and lipid bilayers.

An Z, Lee S, Oppenheimer H, Wesson JA, Ward MD.

J Am Chem Soc. 2010 Sep 29;132(38):13188-90. doi: 10.1021/ja106202y.

PMID:
20812679
16.

Probing crystallization of calcium oxalate monohydrate and the role of macromolecule additives with in situ atomic force microscopy.

Jung T, Sheng X, Choi CK, Kim WS, Wesson JA, Ward MD.

Langmuir. 2004 Sep 28;20(20):8587-96.

PMID:
15379479
17.

Osteopontin is a critical inhibitor of calcium oxalate crystal formation and retention in renal tubules.

Wesson JA, Johnson RJ, Mazzali M, Beshensky AM, Stietz S, Giachelli C, Liaw L, Alpers CE, Couser WG, Kleinman JG, Hughes J.

J Am Soc Nephrol. 2003 Jan;14(1):139-47.

18.

Phosphorylation of osteopontin is required for inhibition of calcium oxalate crystallization.

Wang L, Guan X, Tang R, Hoyer JR, Wierzbicki A, De Yoreo JJ, Nancollas GH.

J Phys Chem B. 2008 Jul 31;112(30):9151-7. doi: 10.1021/jp804282u. Epub 2008 Jul 9.

19.

Exploring calcium oxalate crystallization: a constant composition approach.

Kolbach-Mandel AM, Kleinman JG, Wesson JA.

Urolithiasis. 2015 Oct;43(5):397-409. doi: 10.1007/s00240-015-0781-5. Epub 2015 May 28.

20.

Uropontin in urinary calcium stone formation.

Hoyer JR.

Miner Electrolyte Metab. 1994;20(6):385-92. Review.

PMID:
7783701

Supplemental Content

Support Center